Testimony Before the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee Regarding Using Empagliflozin to Treat Patients with Type 1 Diabetes

View as PDF

In testimony before the Food and Drug Administration’s (FDA’s) Endocrinologic and Metabolic Drugs Advisory Committee, Public Citizen urged the FDA to reject Boehringer Ingelheim’s supplemental new drug application for empagliflozin for treatment of type 1 diabetes because the drug offers minimal benefits that do not outweigh the significantly increased risk of life-threatening diabetic ketoacidosis.